Arrowhead Pharmaceuticals, Inc. announced that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA programme has closed, following early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended.
ARC-LPA is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead’s first drug candidate to use a subcutaneously administered delivery construct.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.